Arbutus Biopharma Corp Stock Z Score
ABUS Stock | USD 2.75 0.11 4.17% |
Arbutus | Z Score |
Arbutus Biopharma Corp Company Z Score Analysis
Arbutus Biopharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Arbutus Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Z Score. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
In accordance with the company's disclosures, Arbutus Biopharma Corp has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 158.7M | 269.2M | 413.3M | 351.7M | 414.9M | 435.6M | |
Enterprise Value | 130.3M | 219.9M | 306.6M | 323.1M | 397.3M | 417.2M |
Arbutus Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Arbutus Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arbutus Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arbutus Biopharma's value.Shares | Millennium Management Llc | 2023-12-31 | 1.5 M | Centiva Capital, Lp | 2023-12-31 | 1.4 M | Advisor Group Holdings, Inc. | 2023-12-31 | 1.4 M | Fourworld Capital Management Llc | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1.1 M | Assenagon Asset Management Sa | 2023-12-31 | 817.6 K | Bank Of New York Mellon Corp | 2023-12-31 | 456.8 K | Boothbay Fund Management, Llc | 2023-12-31 | 453.6 K | Kennedy Capital Management Inc | 2023-12-31 | 387.2 K | Whitefort Capital Management, Lp. | 2023-12-31 | 13.2 M | Blackrock Inc | 2023-12-31 | 10.4 M |
Arbutus Fundamentals
Return On Equity | -0.6 | ||||
Return On Asset | -0.29 | ||||
Operating Margin | (9.57) % | ||||
Current Valuation | 376.32 M | ||||
Shares Outstanding | 180.18 M | ||||
Shares Owned By Insiders | 23.34 % | ||||
Shares Owned By Institutions | 43.91 % | ||||
Number Of Shares Shorted | 4.55 M | ||||
Price To Earning | (1.16) X | ||||
Price To Book | 4.95 X | ||||
Price To Sales | 28.90 X | ||||
Revenue | 18.14 M | ||||
Gross Profit | (45.39 M) | ||||
EBITDA | (76.63 M) | ||||
Net Income | (72.85 M) | ||||
Cash And Equivalents | 150.2 M | ||||
Cash Per Share | 1.00 X | ||||
Total Debt | 8.72 M | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 5.29 X | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | (85.94 M) | ||||
Short Ratio | 7.05 X | ||||
Earnings Per Share | (0.44) X | ||||
Target Price | 4.4 | ||||
Number Of Employees | 73 | ||||
Beta | 2.09 | ||||
Market Capitalization | 495.48 M | ||||
Total Asset | 144.4 M | ||||
Retained Earnings | (1.28 B) | ||||
Working Capital | 109.54 M | ||||
Current Asset | 183.88 M | ||||
Current Liabilities | 10.58 M | ||||
Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Arbutus Stock
0.7 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arbutus Biopharma Piotroski F Score and Arbutus Biopharma Valuation analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.